Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results